Keywords: sonus, reports, higher, losses, usa-based, drug, reformulating
Sonus reports higher losses
Article | 10 February 2003
USA-based drug reformulating company Sonus Pharmaceuticals has reporteda net loss of $2.4 million, or $0.18 per share, for fourth-quarter 2002 compared with $2.1 million, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
